Skip to main content

DETERMINACIÓN DE LA FUNCIÖN Y RELEVANCIA CLNICA DEL REGULADOR DE CELULAS MADRE SOX9 EN ENVEJECIMIENTO Y ENFERMEDADES ASOCIADAS

PI22/01905

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre ASOCIACION INSTITUTO BIODONOSTIA
Execution centre ASOCIACION INSTITUTO BIODONOSTIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Characterization of a Novel Family of Contilisant + Belinostat Multitarget Small Molecules in Glioblastoma

  • Artetxe-Zurutuza, Aizpea
  • Iturrioz-Rodriguez, Nerea
  • Elizazu, Joseba
  • Garcia-Garcia de Garayo, Raul
  • de Goñi, Irati
  • Vergara, Jhonatan
  • Toledano-Pinedo, Mireia
  • Porro-Pérez, Alicia
  • Azkargorta, Mikel
  • Elortza, Felix
  • Marco-Contelles, José
  • Sampron, Nicolás
  • Matheu, Ander
This article belongs to the Special Issue Molecular Mechanisms and Treatment of Brain Cancer: Recent Advances and Future Trends., [Background:] Glioblastoma is the most common and malignant primary brain tumor in adults, with current treatment presenting limited effectiveness. Therapeutic resistance stems largely from its marked molecular and cellular heterogeneity. Multitarget small molecules (MSMs) have emerged as a promising strategy for treating complex diseases such as cancer. In the present work, we generated a novel family of indole-based MSMs engineered to inhibit histone deacetylases (HDACs), monoamine oxidases (MAOs) and cholinesterases (ChEs) while simultaneously acting as histamine H3 receptor (H3R) antagonists and sigma-1 receptor (S1R) agonists., [Methods:] To accomplish this, we combined selected pharmacophoric moieties from the parent compounds Contilisant and the HDAC pan-inhibitor Belinostat. Nine MSMs were synthesized, [Results:] Most of them showed cytotoxic activity in glioma cells. Among them, three molecules (MTP142, MTP156 and MTP150) were prioritized based on potency; these compounds impaired glioma stem cell (GSC) activity and were predicted to cross the blood–brain barrier. In vivo and multi-omic analyses centered on MTP150 showed significant tumor growth inhibition, both as monotherapy and in combination with temozolomide (TMZ). Transcriptomic and proteomic profiling of patient-derived GSCs revealed MTP150-induced disruption of cell cycle regulation pathways., [Conclusions:] Our data reveal the efficacy of a novel family of MSMs in the pre-clinical setting of glioblastoma., A.A.-Z. received a predoctoral fellowship from the Education Department of the Basque Government (PRE_2020_1_0130). N.I.-R. is the recipient of a Sara Borrell postdoctoral contract (CD22/00076) from the Carlos III Institute of Health. We thank the Histology Platform and Animal Facility of the Biogipuzkoa Health Research Institute for their support. This work was supported by Instituto de Salud Carlos III (ISCIII) through the project PI19/01355, PI22/01905, FORT23-00026, DTS24/00153 and co-funded by the European Union and the Health Department of the Basque Country (2022333034, 2023333012) awarded to A.M., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Srr2-dependent SOX2 levels govern the chromatin and transcriptional landscape of adult neural stem cell fate decisions in mouse

  • Cruces-Salguero, Sara
  • Jordán-Pla, Antonio
  • Domingo-Muelas, Ana
  • Morante-Redolat, Jose Manuel
  • Rizzoti, Karine
  • Matheu, Ander
  • Fariñas, Isabel
  • Lovell-Badge, Robin
  • Moncho-Amor, Veronica
21 páginas, 4 figuras, Background: Stem cell maintenance and lineage commitment in the nervous system require precise regulation of transcription factors, with SOX2 serving as a pivotal regulator. SOX2 expression is controlled by multiple enhancers, including the Sox2 regulatory region 2 (Srr2). However, the specific role of Srr2 in adult neurogenesis and chromatin regulation during neural lineage commitment remains incompletely understood. Results: To dissect the function of Srr2, we generate a CRISPR-Cas9 mouse model harboring a targeted deletion of this enhancer. Srr2 deletion reduce SOX2 levels in proliferating, but not differentiating, neurosphere cultures, while impairing both neuronal and oligodendroglial differentiation. Paired bulk RNA-seq and ATAC-seq during proliferation and early differentiation reveal that loss of Srr2 induces widespread chromatin compaction during proliferation, which partially converges toward wild-type states upon early differentiation. Multi-omic integration identifies a subset of neurogenic genes exhibiting persistent promoter closure and impaired transcriptional induction in proliferating mutant cells, despite being normally translated during neural differentiation. In vivo, subependymal zone cells of Srr2del/del mice exhibit lower SOX2 and FOXG1 expression, fewer ASCL1/OLIG2 progenitors, and reduced neuronal and oligodendroglial marker expression. Conclusions: These findings establish Srr2 as a critical enhancer of Sox2 required to maintain a chromatin environment permissive for neural differentiation during stem cell proliferation. Our study underscores the essential role of non-coding regulatory elements in coordinating chromatin accessibility, transcriptional programs, and stem cell fate decisions during adult neurogenesis., Open Access funding provided by The Francis Crick Institute. This work was supported by Instituto de Salud Carlos III (ISCIII) through the project (PI19/01355, PI22/01905, FORT23-00026, DTS24/00153 and PI24/01542) and co-funded by the European Union, and the Health Department of the Basque Country (2022111069, 023333041 and 2024333025). Work at the I.F’s laboratory was supported by grants PID2023-152962NB-I00, CB06/05/0086 (CIBERNED) from Ministerio de Ciencia e Innovación, Prometeo CIPROM/2024/57 from Generalitat Valenciana, and ERC Advanced Grant 101098241 from the European Commission. S.C-S received a predoctoral fellowship from the Ministry of Science, Innovation and Universities (FPU23/01973) and the Spanish Association against Cancer (AECC—PRDGU246336CRUC). V.M-A received a Miguel Servet contract from the Instituto Salud Carlos III (CP23/00111). A.D-M was a recipient of a FPU PhD contract from Ministerio de Educación, Cultura y Deporte (MECD) and her stay at R.L-B’s laboratory was supported by a MECD’s grant included in the FPU program., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Resistance Exercise Intervention Restores Functional Capacity and Improves Frailty Biomarkers in Centenarians

  • Marcos-Perez, Diego
  • Hernandez-Vicente, Adrián
  • Cruces-Salguero, Sara
  • Landa, Jon
  • Bonvini, Michelle
  • Vicente-Rodríguez, German
  • Pueyo, Esther
  • Rodriguez-Mañas, Leocadio
  • Abizanda, Pedro
  • Otaegui, David
  • Garatachea, Nuria
  • Matheu, Ander
Background: Centenarians comprise an age group characterized by exceptional longevity and low age-associated pathologies. However, they still experience physiological decline, and different studies have linked frailty to this population. Exercise interventions reverse frailty and improve functional capacity, but no studies have addressed the effect of an intervention in centenarians. In this study, we assessed the impact of a 12-week resistance exercise intervention in a group of centenarians and characterized their functional capacity as well as the expression of several molecular biomarkers associated with frailty. Methods: A total of 19 centenarians were enrolled, but 7 of them did not complete the study. The remaining 12 centenarians were randomly assigned to the control or intervention group, which was a 12-week resistance exercise intervention. Molecular biomarkers were measured by qRT-PCR and ELISA. Results: The intervention group improved their functional capacity measured by Short Physical Performance Battery (SPPB) (post 5.0 vs 2.3 in pre) and Physical Performance and Mobility Examination (PPME) (6.5 vs 3.8), as well as in frailty status studied by Fried Frailty Phenotype (3.0 vs 3.8) and Frailty Trait Scale 5 (FTS5) (post 30.7 vs 34.0 in pre) scales. ANCOVA revealed that the resistance training led to significant improvements in functional capacity scales SPPB (p = 0.01) and PPME (p < 0.001), as well as Fried Frailty Phenotype (p = 0.001) and FTS5 (p = 0.05). Biomarkers related to frailty (EGR1, miR194-5p, miR125b-5p and miR454-3p) and inflammation (IL-6 and IL-1β) showed different expression patterns in centenarians (n = 19) compared to both old (n = 44, average of 79 years old) and young adults (n = 34, average of 29 years old) groups. Notably, the intervention was associated with improvements in frailty and inflammation biomarkers expression. Finally, correlation analyses showed significant associations between all functional and frailty variables, with SPPB correlating with miR454-3p (ρ = 0.73) and FTS5 correlating with miR454-3p (ρ = −0.83), IL-6 (ρ = 0.60) and miR125b-5p (ρ = −0.55). Conclusions: Our results revealed that resistance exercise intervention enhances functional status and reduces frailty in centenarians, and this is associated with improvements in frailty and inflammation biomarkers.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

A novel class of FKBP12 ligands rescues premature aging phenotypes associated with myotonic dystrophy type 1

  • García Puga, Mikel
  • Gerenu, Gorka
  • Bargiela, Ariadna
  • Espinosa-Espinosa, Jorge
  • Mosqueira-Martín, Laura
  • Sagartzazu-Aizpurua, Maialen
  • Aizpurua, Jesús M.
  • Vallejo-Illarramendi, Ainara
  • Artero, Rubén
  • López de Munain, Adolfo
  • Matheu, Ander
Background: Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder clinically characterized by progressive muscular weakness and multisystem degeneration, which correlates with the size of CTG expansion and MBLN decrease. These changes induce a calcium and redox homeostasis imbalance in several models that recapitulate the features of premature tissue aging. In this study, we characterized the impact of a new family of FKBP12 ligands (generically named MPs or MP compounds) designed to stabilize FKBP12 binding to the ryanodine receptors and normalize calcium dysregulation under oxidative stress. Methods: Human primary fibroblasts from DM1 patients and control donors, treated with MP compounds or not, were used for functional studies of cell viability, proliferation, and metabolism. The gene expression profile in treated cells was determined using RNA sequencing. The impact of MP compounds in vivo was evaluated in a Drosophila model of the disease using locomotor activity and longevity studies. Results: The treatment with different MP compounds reversed oxidative stress and impaired cell viability and proliferation, mitochondrial activity, and metabolic defects in DM1-derived primary fibroblasts. RNA sequencing analysis confirmed the restoration of molecular pathways related to calcium and redox homeostasis and additional pathways, including the cell cycle and metabolism. This analysis also revealed the rescue of alternative splicing events in DM1 fibroblasts treated with MP compounds. Importantly, treatment with MP compounds significantly extended the lifespan and improved the locomotor activity of a Drosophila model of the DM1 disease, and restored molecular defects characteristic of the disease in vivo. Conclusions: Our results revealed that MP compounds rescue multiple premature aging phenotypes described in DM1 models and decipher the benefits of this new family of compounds in the pre-clinical setting of DM1., MG-P and LM-M received a predoctoral fellowship from the University of the Basque Country (PIF 15/245 and PIF19/184, respectively). GG was funded by the Juan de la Cierva-Incorporaci\u00F3n (ISCIII, IJC2019-039965-I) and IKERBASQUE (RF/2023/010) research programs. This work was supported by grants from the Instituto Salud Carlos III and the European Union (PI19/01355, PI21/00557 and PI22/01905), the Health department from Basque Country (2017222021, 2018222021, 2020333008), the Education department from Basque Country (IKUR strategy, NEURODEGENPROT), and the PROMETEO/2020/081 project from the Generalitat Valenciana and CIBERNED funds (CB06/05/1126, Group 609).